CONCLUSIONS	Cannabinoid treatment did not induce psychopathology and did not impair cognition in cannabis-nave patients with MS. However , the positive correlation between blood levels of Delta-9-tetrahydrocannabinol and psychopathological scores suggests that at dosages higher than those used in therapeutic settings , interpersonal sensitivity , aggressiveness , and paranoiac features might arise , although greater statistical power would be necessary to confirm this finding .\